respiratory system agents

Summary

Summary: Drugs used for their effects on the respiratory system.

Top Publications

  1. ncbi Lung function in idiopathic pulmonary fibrosis--extended analyses of the IFIGENIA trial
    Jurgen Behr
    Medizinische Klinik I, Klinikum Grosshadern der Ludwig Maximilians Universität, Munchen, Germany
    Respir Res 10:101. 2009
  2. ncbi Can all patients with COPD use the correct inhalation flow with all inhalers and does training help?
    Raid A M Al-Showair
    School of Pharmacy, Institute of Pharmaceutical Innovation, University of Bradford, Bradford BD7 1DP, UK
    Respir Med 101:2395-401. 2007
  3. ncbi Economic analysis of the Confronting COPD survey: an overview of results
    E F M Wouters
    Department of Pulmonology, University Hospital Maastricht, Maastricht, The Netherlands
    Respir Med 97:S3-14. 2003
  4. ncbi The burden of COPD in the U.S.A.: results from the Confronting COPD survey
    M T Halpern
    Exponent Inc, Alexandria, VA 22314, U SA
    Respir Med 97:S81-9. 2003
  5. ncbi Chronic airflow limitation in developing countries: burden and priorities
    Nadia Aït-Khaled
    International Union Against Tuberculosis and Lung Diseases, Paris, France
    Int J Chron Obstruct Pulmon Dis 2:141-50. 2007
  6. ncbi The burden of COPD in Canada: results from the Confronting COPD survey
    K R Chapman
    University of Toronto, Ontario, Canada
    Respir Med 97:S23-31. 2003
  7. ncbi Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society
    A U Wells
    Royal Infirmary Edinburgh, Little France Crescent, Edinburgh EH16 4SA, UK
    Thorax 63:v1-58. 2008
  8. ncbi The burden of COPD in Italy: results from the Confronting COPD survey
    R Dal Negro
    Divisione Pneumologia, Ospedale Orlandi, Bussolengo, Verona, Italy
    Respir Med 97:S43-50. 2003
  9. ncbi The burden of COPD in The Netherlands: results from the Confronting COPD survey
    E F M Wouters
    Department of Pulmonology, University Hospital Maastricht, Maastricht, The Netherlands
    Respir Med 97:S51-9. 2003
  10. ncbi The burden of COPD in Spain: results from the Confronting COPD survey
    J L Izquierdo
    Pneumology Department, Hospital General Universitario de Guadalajara, Spain
    Respir Med 97:S61-9. 2003

Research Grants

  1. Role of Mucin in Lung Homeostasis and Pathophysiology
    Christopher M Evans; Fiscal Year: 2010
  2. Central Mechanisms of Respiratory Arrest
    Fadi Xu; Fiscal Year: 2007
  3. Prospective Study of Dietary Factors, BMI, and Risk of Asthma in Children
    Carlos Camargo; Fiscal Year: 2007
  4. BACKGROUND POTASSIUM CHANNELS AS ANESTHETIC TARGETS
    CHARLES YOST; Fiscal Year: 2007
  5. Smoke Induced Airway Injury in COPD
    JEANINE D ARMIENTO; Fiscal Year: 2007
  6. Smoke Induced Airway Injury in COPD
    JEANINE M D apos ARMIENTO; Fiscal Year: 2010
  7. Smoke Induced Airway Injury in COPD
    JEANINE D ARMIENTO; Fiscal Year: 2009
  8. BACKGROUND POTASSIUM CHANNELS AS ANESTHETIC TARGETS
    CHARLES YOST; Fiscal Year: 2003
  9. BACKGROUND POTASSIUM CHANNELS AS ANESTHETIC TARGETS
    CHARLES YOST; Fiscal Year: 2000
  10. CEREBELLUM--ROLE IN THE CHEMICAL CONTROL OF BREATHING
    Fadi Xu; Fiscal Year: 2003

Detail Information

Publications119 found, 100 shown here

  1. ncbi Lung function in idiopathic pulmonary fibrosis--extended analyses of the IFIGENIA trial
    Jurgen Behr
    Medizinische Klinik I, Klinikum Grosshadern der Ludwig Maximilians Universität, Munchen, Germany
    Respir Res 10:101. 2009
    ..To better understand the clinical implications of these findings we performed additional, explorative analyses of the IFGENIA data set...
  2. ncbi Can all patients with COPD use the correct inhalation flow with all inhalers and does training help?
    Raid A M Al-Showair
    School of Pharmacy, Institute of Pharmaceutical Innovation, University of Bradford, Bradford BD7 1DP, UK
    Respir Med 101:2395-401. 2007
    ..Some COPD patients have problems achieving required PIFs through DPIs but training is useful to help some exceed the minimum required rate despite only small improvements. The patients found it easier to slow their PIF through the MDI...
  3. ncbi Economic analysis of the Confronting COPD survey: an overview of results
    E F M Wouters
    Department of Pulmonology, University Hospital Maastricht, Maastricht, The Netherlands
    Respir Med 97:S3-14. 2003
    ....
  4. ncbi The burden of COPD in the U.S.A.: results from the Confronting COPD survey
    M T Halpern
    Exponent Inc, Alexandria, VA 22314, U SA
    Respir Med 97:S81-9. 2003
    ..The results of the survey suggest that interventions that improve COPD outcomes by decreasing symptoms and preventing acute exacerbations could substantially decrease the costs associated with this disease...
  5. ncbi Chronic airflow limitation in developing countries: burden and priorities
    Nadia Aït-Khaled
    International Union Against Tuberculosis and Lung Diseases, Paris, France
    Int J Chron Obstruct Pulmon Dis 2:141-50. 2007
    ....
  6. ncbi The burden of COPD in Canada: results from the Confronting COPD survey
    K R Chapman
    University of Toronto, Ontario, Canada
    Respir Med 97:S23-31. 2003
    ..Early diagnosis and the application of available but underused interventions (e.g. smoking cessation, inhaled drug therapies and pulmonary rehabilitation) could reduce the morbidity and costs of COPD in this country...
  7. ncbi Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society
    A U Wells
    Royal Infirmary Edinburgh, Little France Crescent, Edinburgh EH16 4SA, UK
    Thorax 63:v1-58. 2008
  8. ncbi The burden of COPD in Italy: results from the Confronting COPD survey
    R Dal Negro
    Divisione Pneumologia, Ospedale Orlandi, Bussolengo, Verona, Italy
    Respir Med 97:S43-50. 2003
    ....
  9. ncbi The burden of COPD in The Netherlands: results from the Confronting COPD survey
    E F M Wouters
    Department of Pulmonology, University Hospital Maastricht, Maastricht, The Netherlands
    Respir Med 97:S51-9. 2003
    ..In addition, smoking cessation intervention at the early stages of the disease could help to reduce the high costs associated with severe COPD in this country...
  10. ncbi The burden of COPD in Spain: results from the Confronting COPD survey
    J L Izquierdo
    Pneumology Department, Hospital General Universitario de Guadalajara, Spain
    Respir Med 97:S61-9. 2003
    ..Therefore, introducing interventions to reduce the progression to severe COPD could also reduce the impact of the disease...
  11. ncbi The burden of COPD in the U.K.: results from the Confronting COPD survey
    M Britton
    St Peter s Hospital, Chertsey, U K
    Respir Med 97:S71-9. 2003
    ....
  12. ncbi Structural changes in airway diseases: characteristics, mechanisms, consequences, and pharmacologic modulation
    Celine Bergeron
    Hôpital Laval 2725, Chemin Sainte Foy, Quebec, QC, Canada
    Chest 129:1068-87. 2006
    ..The potential of novel therapeutic agents to reverse or prevent airway remodeling is an exciting avenue and warrants further evaluation...
  13. ncbi Chronic obstructive pulmonary disease: the clinical management of an acute exacerbation
    J R Hurst
    Academic Unit of Respiratory Medicine, Dominion House, St Bartholomew's Hospital, London EC1A 7BE, UK
    Postgrad Med J 80:497-505. 2004
    ..In this review we aim to bring the non-specialist reader up to date with current management principles and the evidence underlying such interventions...
  14. ncbi Physiology of airway mucus secretion and pathophysiology of hypersecretion
    Duncan F Rogers
    Airway Disease, National Heart and Lung Institute, Imperial College London, Dovehouse Street, London, United Kingdom, SW3 6LY
    Respir Care 52:1134-46; discussion 1146-9. 2007
    ....
  15. ncbi Respiratory medicine
    Hilary Pinnock
    Department of General Practice and Primary Care, University of Aberdeen
    Br J Gen Pract 54:539-47. 2004
    ..In this paper the key recommendations of these guidelines and their implementation in the pragmatic world of general practice are discussed, with specific focus on diagnosis, monitoring, management, self-management and delivery of care...
  16. ncbi Periextubation caffeine in preterm neonates: a randomized dose response trial
    P A Steer
    Centre for Clinical Studies, University of Queensland, Queensland, Australia
    J Paediatr Child Health 39:511-5. 2003
    ..To compare the effectiveness of three dosing regimens of caffeine for preterm infants in the periextubation period...
  17. ncbi [Objective criteria for assessing benefits of therapy in COPD - ATS/ERS guidelines 2007]
    A Cuvelier
    , CHU de Rouen et UPRES EA 3830 (IFR MP23, , , 76031 Rouen Cedex, France
    Rev Mal Respir 24:827-9. 2007
  18. ncbi Nonpharmacological and pharmacological interventions to prevent or reduce airway remodelling
    E H Walters
    Cardio Respiratory Research Group, Menzies Research Institute, University of Tasmania, 43 Collins Street, Hobart 7001, Australia
    Eur Respir J 30:574-88. 2007
    ..The areas where it is believed urgent research needs to be focused have also been highlighted...
  19. ncbi Effect of doxapram on cerebral blood flow velocity in preterm infants
    C Roll
    Klinik und Poliklinik für Kinder und Jugendmedizin, Universitatsklinikum Essen, Essen, Germany
    Neuropediatrics 35:126-9. 2004
    ..As an unwanted side effect, reduced cerebral perfusion has been seen in methylxanthine-treated infants while effects of doxapram on the cerebral perfusion have not been studied yet...
  20. ncbi COPD exacerbations. 4: Prevention
    S Scott
    Division of Infection and Immunity, Clinical Sciences Centre, University Hospital Aintree, Liverpool L9 7AL, UK
    Thorax 61:440-7. 2006
  21. ncbi High dose caffeine citrate for extubation of preterm infants: a randomised controlled trial
    P Steer
    Department of Neonatology and Centre for Clinical Studies, University of Queensland, Mater Health Services, South Brisbane, Australia
    Arch Dis Child Fetal Neonatal Ed 89:F499-503. 2004
    ..To compare two dosing regimens for caffeine citrate in the periextubation period for neonates born at less than 30 weeks gestation in terms of successful extubation and adverse effects...
  22. ncbi Olfactory stimulation prevents apnea in premature newborns
    Luc Marlier
    Centre National de la Recherche Scientifique, UMR 5170, site of Strasbourg, France
    Pediatrics 115:83-8. 2005
    ..The present study examines whether exposure to an odor known to modulate the infant's respiratory rate could reduce the frequency of apneic spells...
  23. ncbi Treatment of airway mucus hypersecretion
    Duncan F Rogers
    Section of Airway Disease, National Heart and Lung Institute, Imperial College London, UK
    Ann Med 38:116-25. 2006
    ..More information is required on these differences to identify specific therapeutic targets which, in turn, should lead to rational design of anti-hypersecretory drugs for treatment of airway mucus hypersecretion in asthma and COPD...
  24. ncbi ABC of chronic obstructive pulmonary disease. Acute exacerbations
    Graeme P Currie
    Respiratory Unit, Aberdeen Royal Infirmary, Aberdeen
    BMJ 333:87-9. 2006
  25. ncbi The transient receptor potential vanilloid 1: role in airway inflammation and disease
    Pierangelo Geppetti
    Clinical Pharmacology Unit, Department of Critical Care Medicine and Surgery, University of Florence, Italy
    Eur J Pharmacol 533:207-14. 2006
    ..TRPV1 antagonists may be useful in the treatment of these diseases...
  26. ncbi Nanomedicine for respiratory diseases
    Ulrich Pison
    Department of Anesthesiology and Intensive Care Medicine, Charite Universitatsmedizin Berlin, D 13353 Berlin, Germany
    Eur J Pharmacol 533:341-50. 2006
    ..Based on the recent progress in nanobiotechnology there is potential for nanoparticles and -systems to become useful tools as therapeutic and diagnostic tools in the near future...
  27. ncbi An algorithm for the identification of undiagnosed COPD cases using administrative claims data
    Douglas W Mapel
    Lovelace Clinic Foundation, Albuquerque, New Mexico 87106 4264, USA
    J Manag Care Pharm 12:457-65. 2006
    ..This undiagnosed COPD negatively affects health status, and COPD patients may have increased health care utilization several years before the initial diagnosis of COPD is made...
  28. ncbi Doxapram and developmental delay at 12 months in children born extremely preterm
    Ane Lando
    Department of Neonatology, The Juliane Marie Centre, Copenhagen University Hospital, Copenhagen, Denmark
    Acta Paediatr 94:1680-1. 2005
    ..To examine the relation of doxapram to a developmental score achieved by a structured telephone interview in a group of extremely-preterm-born children...
  29. ncbi The airway pathophysiology of COPD: implications for treatment
    Roberto Rodriguez-Roisin
    Servei de Pneumologia, Institut d lnvestigacions Biomèdiques August Pi i Sunyer IDIBAPS, Hospital Clinic, Universitat de Barcelona, Villaroel, 170, 08036 Barcelona, Spain
    COPD 2:253-62. 2005
    ....
  30. ncbi Brain hemodynamic effects of doxapram in preterm infants
    Carlo Dani
    Department of Surgical and Medical Critical Care, Section of Neonatology, Careggi University Hospital of Florence, Florence, Italy
    Biol Neonate 89:69-74. 2006
    ....
  31. ncbi A new look at the respiratory stimulant doxapram
    C Spencer Yost
    Department of Anesthesia and Perioperative Care, University of California at San Francisco, San Francisco, California 94143, USA
    CNS Drug Rev 12:236-49. 2006
    ..Although it is unlikely that doxapram will undergo a clinical renaissance based on this new understanding, it represents a significant advance in our knowledge of the control of breathing...
  32. ncbi Ovalbumin sensitization alters the ventilatory responses to chemical challenges in guinea pigs
    Fadi Xu
    Pathophysiology Program, Lovelace Respiratory Research Institute, 2425 Ridgecrest Dr SE, Albuquerque, NM 87108, USA
    J Appl Physiol 99:1782-8. 2005
    ....
  33. ncbi Prediction of panic response to a respiratory stimulant by reduced orbitofrontal cerebral blood flow in panic disorder
    Justine M Kent
    Department of Psychiatry, Unit 41, Columbia University, 1051 Riverside Drive, New York, NY 10032, USA
    Am J Psychiatry 162:1379-81. 2005
    ..The aim of this study was to examine regional cerebral blood flow changes in response to anxiety/panic provocation in subjects with panic disorder and healthy comparison subjects...
  34. ncbi Doxapram stimulates the carotid body via a different mechanism than hypoxic chemotransduction
    Toru Takahashi
    First Department of Medicine, Asahikawa Medical College, 2 1 1 1 Midorigaoka Higash, Asahikawa 078 8510, Japan
    Respir Physiol Neurobiol 147:1-9. 2005
    ..Neither pinacidil nor levcromakalim affected the stimulatory effect of doxapram. We conclude that doxapram stimulates the carotid body via a different mechanism than hypoxic chemotransduction...
  35. ncbi Plethysmographic comparison of breathing pattern in heaves (recurrent airway obstruction) versus experimental bronchoconstriction or hyperpnea in horses
    Andrew M Hoffman
    Lung Function Testing Laboratory, Department of Clinical Sciences, Tufts University School of Veterinary Medicine, North Grafton, MA, USA
    J Vet Intern Med 21:184-92. 2007
    ..Horses with recurrent airway obstruction (heaves) are described as exhibiting "increased abdominal effort," but it is unknown whether this translates to an effective contribution to ventilation...
  36. ncbi Doxapram shortens recovery following sevoflurane anesthesia
    Chi Chen Wu
    Department of Anesthesiology, Taipei Medical University Hospital, 252 Wu Hsin Street, Taipei, Taiwan 110
    Can J Anaesth 53:456-60. 2006
    ..A randomized, double blind controlled trial was undertaken to investigate the effect of doxapram on recovery times and bispectral index following sevoflurane anesthesia...
  37. ncbi Doxapram produces a dose-dependent reduction in the shivering threshold in rabbits
    Katsumi Okuyama
    Department of Anesthesia, University of Yamanashi, Faculty of Medicine, Tamaho, Yamanashi, Japan
    Anesth Analg 97:759-62. 2003
    ..50 mg x kg(-1) x h(-1) shivered at 33.7 degrees +/- 0.6 degrees C. All the shivering thresholds significantly (P < 0.001) differed from one another. The magnitude of this inhibition, if similar in humans, would be clinically important...
  38. ncbi Effects of almitrine bismesylate on arterial blood gases in patients with chronic obstructive pulmonary disease and moderate hypoxaemia: a multicentre, randomised, double-blind, placebo-controlled study
    D Gorecka
    Department of Respiratory Medicine, Institute of Tuberculosis and Lung Diseases, Warsaw, Poland
    Respiration 70:275-83. 2003
    ..Almitrine bismesylate has been shown to improve gas exchange in the lungs. Our hypothesis was that long-term treatment with almitrine might postpone the prescription of LTOT...
  39. ncbi The effects of doxapram hydrochloride (dopram-V) on laryngeal function in healthy dogs
    Carrie Jean Miller
    Denver Veterinary Specialists, Wheat Ridge, CO 80033, USA
    J Vet Intern Med 16:524-8. 2002
    ..We propose the routine use of doxapram during laryngoscopy to increase intrinsic laryngeal motion and aid in the diagnosis of laryngeal dysfunction...
  40. ncbi Managing acute on chronic respiratory failure: a guide to non-invasive ventilation
    J J P Goldring
    Royal Free and University College Medical School, London NW3 2PF
    Br J Hosp Med (Lond) 69:444-9. 2008
    ..It is associated with high mortality rates and so practising the best evidence-based management is vital...
  41. ncbi Pharmacoeconomics in COPD: lessons for the future
    Helen J Starkie
    Public Health and Health Policy, University of Glasgow, Glasgow, UK
    Int J Chron Obstruct Pulmon Dis 3:71-88. 2008
    ....
  42. ncbi Doxapram and perception of dyspnea
    Satoru Ebihara
    Chest 121:1380-1. 2002
  43. ncbi Management of an acute exacerbation of copd: are we ignoring the evidence?
    M K Johnson
    Department of Respiratory Medicine, Glasgow Royal Infirmary, UK
    Thorax 57:II15-II23. 2002
  44. ncbi Current and future therapies for airway mucus hypersecretion
    Peter J Barnes
    National Heart and Lung Institute, Imperial College School of Medicine, Dovehouse Street, London SW3 6LY, UK
    Novartis Found Symp 248:237-49; discussion 249-53, 277-82. 2002
    ..However, the clinical benefits from inhibiting mucus hypersecretion are still not certain, casting some doubts on this therapeutic approach...
  45. ncbi Clinical evaluation of new therapies for treatment of mucus hypersecretion in respiratory diseases
    Bernd Disse
    Department of Therapeutic Area Respiratory Diseases, Boehringer Ingelheim Pharma KG, PO Box 200, 55216 Ingelheim, Germany
    Novartis Found Symp 248:254-72; discussion 272-6, 277-82. 2002
    ..Proof for no depression of lung mucociliary clearance is an important safety endpoint...
  46. ncbi Treatment of apnea of prematurity
    Varsha Bhatt-Mehta
    Department of Clinical Sciences, College of Pharmacy, University of Michigan, F5203, 200 East Hospital Drive, Ann Arbor, MI 48109, USA
    Paediatr Drugs 5:195-210. 2003
    ..The decision to provide a home apnea monitor should be individualized for each patient, depending on the effectiveness of treatment and clinical response...
  47. ncbi PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilast
    Victoria Boswell Smith
    The Sackler Institute of Pulmonary Pharmacology, King s College London School of Biomedical and Health Sciences, King s College London, Guys Campus, UK
    Int J Chron Obstruct Pulmon Dis 2:121-9. 2007
    ..This review will discuss the current standing of PDE4 inhibitors like roflumilast as novel treatments for COPD and the potential for developing nonemetic anti-inflammatory drugs...
  48. ncbi Long-term effects of almitrine bismesylate in COPD patients with chronic hypoxaemia
    J Sans-Torres
    S Pneumologia, H de Sabadell Corporació Parc Taulí, UAB, Barcelona, Spain
    Respir Med 97:599-605. 2003
    ..We studied the long-term effects of AB in COPD patients with chronic hypoxaemia...
  49. ncbi Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease--2003
    Denis E O'Donnell
    Division of Respiratory and Critical Care Medicine, Department of Medicine, Queen s University, 102 Stuart Street, Kingston, Ontario K7L 2V6, Canada
    Can Respir J 10:11A-65A. 2003
    ..Patients with advanced COPD and respiratory failure require a comprehensive management plan that incorporates structured end-of-life care...
  50. ncbi [Respiratory diseases in infants hospitalized during the 1st 2 years of life for viral lower respiratory tract infections: a one-year follow-up]
    M Giovannini
    Clinica Pediatrica Ospedale San Paolo, , Milano, Italy
    Minerva Pediatr 55:149-55. 2003
    ....
  51. ncbi Rodent doxapram model of panic: behavioral effects and c-Fos immunoreactivity in the amygdala
    Gregory M Sullivan
    Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
    Biol Psychiatry 53:863-70. 2003
    ..Doxapram is a respiratory stimulant that reliably evokes panic attacks in patients with panic disorder. We examined doxapram in four rodent models of anxiety and sought to identify brain regions involved in its behavioral effects...
  52. ncbi Effect of position, nitric oxide, and almitrine on lung perfusion in a porcine model of acute lung injury
    J C Richard
    Service de Réanimation Médicale et Assistance Respiratoire, Lyon 69004, France
    J Appl Physiol 93:2181-91. 2002
    ..001). A ventral redistribution of PBF was also obtained with iNO regardless of the position (P = 0.043). Adjunction of ivALM had no further effect on PBF redistribution. PP and iNO have an additive effect on ventral redistribution of PBF...
  53. ncbi Development of inhalable dry powder formulation of basic fibroblast growth factor
    Basma M Ibrahim
    Department of Industrial and Physical Pharmacy, Purdue University, 575 Stadium Mall Drive, West Lafayette, IN 47907, United States
    Int J Pharm 385:66-72. 2010
    ..2+/-5.4% and mass median aerodynamic diameter of 4.7+/-0.9 microm) and 98.1+/-7% recovery of bioactive bFGF. This result warrants further investigation of the biological activity of the inhaled bFGF in a disease model...
  54. ncbi Respiratory and cardiovascular effects of doxapram and theophylline for the treatment of asphyxia in neonatal calves
    U Bleul
    Clinic of Reproductive Medicine, Department of Food Animals, Vetsuisse Faculty University of Zurich, Zurich, Switzerland
    Theriogenology 73:612-9. 2010
    ..Doxapram, but not theophylline, is indicated for treatment of postnatal asphyxia in calves, but there are potential cardiovascular side effects...
  55. ncbi Correlates of adherence to respiratory drugs in COPD patients
    Laurent Laforest
    Unité de Neuro Pharmaco Epidémiologie, CHU University Hospital Lyon, Lyon, France
    Prim Care Respir J 19:148-54. 2010
    ..To identify the correlates of accidental omissions and intentional interruptions of respiratory therapy in COPD...
  56. ncbi Small airway disease: a riddle wrapped in a mystery inside an enigma
    Gene L Colice
    J Allergy Clin Immunol 118:337-9. 2006
  57. ncbi Association of obstructive sleep apnea risk with asthma control in adults
    Mihaela Teodorescu
    Medical Service, William S Middleton Memorial Veterans Hospital, Madison, WI, USA
    Chest 138:543-50. 2010
    ..Unrecognized obstructive sleep apnea (OSA) may lead to poor asthma control despite optimal therapy. Our objective was to evaluate the relationship between OSA risk and asthma control in adults...
  58. ncbi Should I wheel out the heliox with non-invasive ventilation?
    Paul Downie
    Centre for Anaesthesia, UCL, London NW1 2BU
    Br J Hosp Med (Lond) 67:220. 2006
  59. ncbi Symptom variability in patients with severe COPD: a pan-European cross-sectional study
    R Kessler
    Dept of PneumologyNouvel Hôpital Civil, Strasbourg 67000, France
    Eur Respir J 37:264-72. 2011
    ..Patient-perceived COPD symptoms vary over the day and the week, and impact on daily activities; morning being the worst time of day. The majority of patients appear not to adjust treatment when symptoms worsen...
  60. ncbi Respiratory and mental health effects of wildfires: an ecological study in Galician municipalities (north-west Spain)
    Francisco Caamaño-Isorna
    Consortium for Biomedical Research in Epidemiology and Public Health, Department of Preventive Medicine, University of Santiago de Compostela, Spain
    Environ Health 10:48. 2011
    ..This study sought to analyse the respiratory and mental health effects of the August-2006 fires, using consumption of anxiolytics-hypnotics and drugs for obstructive airway diseases as indicators...
  61. ncbi Drug consumption and air pollution: an overview
    Federica Menichini
    Faculty of Pharmacy and Nutrition and Health Sciences, Department of Pharmaceutical Sciences, University of Calabria, Arcavacata di Rende, Italy
    Pharmacoepidemiol Drug Saf 19:1300-15. 2010
    ..Acute respiratory symptoms are among the health effects of air pollution exposure. Studies over the past decades have linked respiratory drug use (consumption or sales) with changes in air pollution conditions...
  62. ncbi Discontinued drugs, 2007: pulmonary-allergy, dermatological, gastrointestinal and arthritis drugs
    Sabina A Antoniu
    Gr T Popa University of Medicine and Pharmacy Iasi, Pulmonary Disease University Hospital, Division of Pulmonary Disease, Iasi, Romania asi ro
    Expert Opin Investig Drugs 17:1651-61. 2008
    ..Information for this perspective was derived from a search of the Pharmaprojects database for drugs discontinued after reaching Phase I - III clinical trials...
  63. ncbi Inhibitory effects of synthetic somatostatin receptor subtype 4 agonists on acute and chronic airway inflammation and hyperreactivity in the mouse
    Krisztian Elekes
    Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, University of Pecs, H 7624 Pecs, Szigeti u 12, Hungary
    Eur J Pharmacol 578:313-22. 2008
    ....
  64. ncbi Establishing standardised methods for comparing aqueous droplet inhalers
    E Berg
    AstraZeneca R and D, Analytical Development, Scheelevagen 2, S 221 87 Lund, Sweden
    Pharmeur Sci Notes 2006:9-15. 2006
    ....
  65. ncbi Dynamic QT/RR relationship of cardiac conduction in premature infants treated with low-dose doxapram hydrochloride
    Masafumi Miyata
    Department of Pediatrics, School of Medicine, Fujita Health University Toyoake, Aichi, Japan
    J Perinat Med 35:330-3. 2007
    ..We conclude that low-dose administration of doxapram hydrochloride did not have any undesirable effects on myocardial depolarization and repolarization...
  66. ncbi FDA: cold medications risky for young children
    Bridget M Kuehn
    JAMA 298:1151. 2007
  67. ncbi Pirfenidone in idiopathic pulmonary fibrosis: the CAPACITY program
    Luca Richeldi
    University of Modena and Reggio Emilia, Modena, Italy
    Expert Rev Respir Med 5:473-81. 2011
    ..It is likely that pirfenidone will be utilised in many countries as first-line therapy and will also be included in studies of combination therapy for this attritional disease...
  68. ncbi Emerging therapies for treatment of acute lung injury and acute respiratory distress syndrome
    Karen J Bosma
    University of Western Ontario, Division of Respirology, London Health Sciences Centre, University Hospital, 339 Windermere Road, London, Ontario, N6A 5A5, Canada
    Expert Opin Emerg Drugs 12:461-77. 2007
    ....
  69. ncbi Low-tidal-volume ventilation
    Laurent Chiche
    N Engl J Med 357:2518-9; author reply 2519-20. 2007
  70. ncbi Minimizing variability of cascade impaction measurements in inhalers and nebulizers
    Matthew Bonam
    Analytical Development, AstraZeneca Charnwood, Loughborough, Leicestershire, UK
    AAPS PharmSciTech 9:404-13. 2008
    ....
  71. ncbi Respiratory drug market dynamics
    Lisette Oversteegen
    Nat Rev Drug Discov 6:695-6. 2007
  72. ncbi An overview of erdosteine antioxidant activity in experimental research
    Maurizio Moretti
    Clinica di Malattie dell Apparato Respiratorio, Dipartimento di Oncologia, Ematologia e Patologie Apparato Respiratorio, Universita di Modena e Reggio Emilia, Policlinico, Largo del Pozzo 71, 41100 Modena, Italy
    Pharmacol Res 55:249-54. 2007
    ..Recent positive clinical trials in humans seem to fulfill the impressive promises that theory and experimental research have put forward...
  73. ncbi Solid-state chemistry of ambroxol theophylline-7-acetate
    Anastasia Foppoli
    Istituto di Chimica Farmaceutica e Tossicologica Pietro Pratesi, University of Milano, 20131 Milano, Italy
    J Pharm Sci 96:1139-46. 2007
    ....
  74. ncbi Hayfever--practical management issues
    Andrew Ross
    Br J Gen Pract 54:412-4. 2004
  75. ncbi Interventions to prevent chronic obstructive pulmonary disease exacerbations
    Dennis E Niewoehner
    Pulmonary Section, Veterans Affairs Medical Center, and Department of Medicine, University of Minnesota, Minneapolis, Minnesota 55417, USA
    Am J Med 117:41S-48S. 2004
    ..This article discusses pharmacologic therapy and other measures for preventing exacerbations and hospitalizations due to exacerbations of COPD...
  76. ncbi Long-term progestin therapy for female chronic respiratory insufficiency?
    Tarja Saaresranta
    Department of Pulmonary Diseases, Turku University Central Hospital, Kiinamyllynkatu 4 8, 20520 Turku, Finland
    Respir Med 98:194-5. 2004
    ..This case documents successful control of chronic respiratory failure with medroxyprogesterone in a postmenopausal woman during 1-year follow-up...
  77. ncbi [Costs of chronic obstructive pulmonary disease in Spain. Estimation from a population-based study]
    J F Masa

    Arch Bronconeumol 40:72-9. 2004
    ..The cost distribution is not in line with recommended health care practices, underlining the need to optimize resources used to monitor and treat the disease, with an emphasis on early diagnosis...
  78. ncbi pO2 - Do we treat the right thing?
    D Kohler
    Respiration 70:455-6. 2003
  79. ncbi Beneficial effects of a novel anti-hypoxemic agent, TEI-7322, on bleomycin-induced experimental hypoxemia in rats
    H Horiuchi
    Teijin Institute for Bio Medical Research, Hino, Tokyo, Japan
    Eur J Pharmacol 287:27-34. 1995
    ....
  80. ncbi Therapeutic, toxic, and lethal concentrations of 73 drugs affecting respiratory system in human fluids
    M R Repetto
    National Institute of Toxicology, Seville, Spain
    J Toxicol Clin Toxicol 36:287-93. 1998
    ..Drugs affecting the respiratory system are an important group of pharmaceutical specialties in poisoning with relatively high frequency...
  81. ncbi Isolated mental developmental delay in very low birth weight infants: association with prolonged doxapram therapy for apnea
    C Sreenan
    Neonatal Intensive Care Unit and Department of Perinatology, Royal Alexandra Hospital, Edmonton, Alberta, Canada
    J Pediatr 139:832-7. 2001
    ..We investigated factors associated with isolated mental delay in infants weighing < 1250 g at birth...
  82. ncbi Flowmetric comparison of respiratory inductance plethysmography and pneumotachography in horses
    A Hoffman
    Department of Clinical Sciences, Tufts University School of Veterinary Medicine, North Grafton, MA 01536, USA
    J Appl Physiol 91:2767-75. 2001
    ..01) increases in SFE(max) but not in SFE(int). In conclusion, dynamic comparisons between RIP and Pn provide a defensible method for quantifying AO during tidal breathing, without the need for invasive instrumentation...
  83. ncbi A study of the effect of nasal steroid sprays in perennial allergic rhinitis patients with rhinitis medicamentosa
    B J Ferguson
    University of Pittsburgh School of Medicine, Eye and Ear Institute and the Department of Otolaryngology, Pennsylvania 15213, USA
    Otolaryngol Head Neck Surg 125:253-60. 2001
    ..To determine if rebound congestion can be reduced with concomitant nasal steroid spray usage...
  84. ncbi The variability and repeatability of indices derived from the single-breath diagram for CO2 in horses with chronic obstructive pulmonary disease and the effect of lobelin hydrochloride on these indices
    C Herholz
    Department of Equine Internal Medicine, Faculty of Veterinary Medicine, University of Berne, Switzerland
    Vet Res Commun 25:401-12. 2001
    ..Stimulating respiration with Lobelin gave no advantage in the repeatability of the lung function indices or in differentiating between horses with different degrees of COPD...
  85. ncbi Low-dose doxapram for treatment of apnoea following early weaning in very low birthweight infants: a randomized, double-blind study
    C Huon
    Service de médecine néonatale de Port Royal, Centre Hospitalier Universitaire Cochin Port Royal, Universite Rene Descartes, Paris, France
    Acta Paediatr 87:1180-4. 1998
    ..It is therefore suggested that doxapram, even at low doses, should not be used during the first few days of life. Careful monitoring of blood pressure is required if doxapram is used later...
  86. ncbi Effect of almitrine on upper airway muscle contraction in young and old rats
    D Cantillon
    Department of Physiology, Royal College of Surgeons in Ireland, St Stephen s Green, 2, Dublin, Ireland
    Eur J Pharmacol 412:187-94. 2001
    ..However, almitrine increases resistance to fatigue in both muscles in young but not in old rats...
  87. ncbi Dose-dependent effects of almitrine on hemodynamics and gas exchange in an animal model of acute lung injury
    A Sommerer
    Abteilung X, Anaesthesiologie und Intensivmedizin, Bundeswehrkrankenhaus Berlin, Germany
    Intensive Care Med 26:434-41. 2000
    ..To determine the dose-response relationship of almitrine (Alm) on pulmonary gas exchange and hemodynamics in an animal model of acute lung injury (ALI)...
  88. ncbi Doxapram accentuates white matter injury in neonatal rats following bilateral carotid artery occlusion
    H Uehara
    Department of Pediatrics, Kyoto Prefectural University of Medicine, Kawaramachi Hirokoji, Kamigyo ku, Kyoto, Japan
    Neurosci Lett 281:191-4. 2000
    ..1.70+/-0.48, P<0.05) and in the subcortical white matter (0.33+/-0. 67 vs. 1.10+/-0.54, P<0.05). These results demonstrated that the use of doxapram under an ischemic condition accentuates white matter damage in neonatal rats...
  89. ncbi Treatment of hypoxemia during one-lung ventilation using intravenous almitrine
    Nicolas Dalibon
    Department of Anesthesiology, Hopital Foch, Universite Paris Ouest, Suresnes, France
    Anesth Analg 98:590-4, table of contents. 2004
    ..01). Heart rate, arterial blood pressure, and cardiac index did not change throughout the study, but we could obtain an adequate aortic blood flow signal in only half of the patients. Almitrine could be used to treat hypoxemia during OLV...
  90. ncbi Lung growth induced by prenatal instillation of perfluorocarbon into the fetal rabbit lung
    Oliver J Muensterer
    Department of Pediatric Surgery, University of Munich, Dr von Hauner Children s Hospital, Lindwurmstrasse 4, 80337 Munich, Germany
    Pediatr Surg Int 20:248-52. 2004
    ..This novel technique may be a less invasive and less noxious treatment strategy for pulmonary hypoplasia associated with diaphragmatic hernia...
  91. ncbi Carrier-based strategies for targeting protein and peptide drugs to the lungs
    Sally Ann Cryan
    School of Pharmacy, Royal College of Surgeons in Ireland, Dublin 2, Ireland
    AAPS J 7:E20-41. 2005
    ..The emphasis in this review will be on targeting of protein/peptide drugs by inhalation using carriers and ligands...
  92. ncbi Bilateral recurrent laryngeal neurectomy as a model for the study of idiopathic canine laryngeal paralysis
    C L Greenfield
    Department of Veterinary Clinical Medicine, University of Illinois, College of Veterinary Medicine, Urbana 61802, USA
    Can Vet J 38:163-7. 1997
    ..We concluded that bilateral recurrent laryngeal neurectomy resulted in clinical signs and respiratory changes similar to those of idiopathic canine laryngeal paralysis...
  93. ncbi Effect of inhaled prostacyclin in combination with almitrine on ventilation-perfusion distributions in experimental lung injury
    R Dembinski
    Department of Anesthesiology, Universitaetsklinikum der RWTH Aachen, Germany
    Anesthesiology 94:461-7. 2001
    ..This study was performed to investigate a possible additive effect of prostacyclin and almitrine on pulmonary ventilation-perfusion (VA/Q) ratio in ALI compared with inhaled prostacyclin or intravenous almitrine alone...
  94. ncbi Additive beneficial effects of the prone position, nitric oxide, and almitrine bismesylate on gas exchange and oxygen transport in acute respiratory distress syndrome
    P Jolliet
    Medical ICU Division, University Hospital, Geneva, Switzerland
    Crit Care Med 25:786-94. 1997
    ....
  95. ncbi [Obesity and hypoventilation syndrome; effects of weight loss and treatment with respiratory stimulants]
    M Koziej
    Kliniki Chorób Płuc, Warszawie
    Pneumonol Alergol Pol 64:687-96. 1996
    ..Causes, pathophysiology and possible treatment of obesity-hypoventilation syndrome are discussed...
  96. ncbi Deposition of inhaled particles in the human respiratory tract and consequences for regional targeting in respiratory drug delivery
    Joachim Heyder
    GSF National Research Center for Environment and Health, Institute for Inhalation Biology, D 85758 Neuherberg Munich, Germany
    Proc Am Thorac Soc 1:315-20. 2004
    ..Effective targeting of the bronchial region can only be achieved with bolus inhalations. When particles are suspended in a gas heavier than air, targeting the alveolar region can be enhanced...
  97. ncbi UK guidelines for the use of inhaled nitric oxide therapy in adult ICUs. American-European Consensus Conference on ALI/ARDS
    B H Cuthbertson
    Anaesthesia and Intensive Care, Institute of Medical Sciences, Medical School, University of Aberdeen, Scotland
    Intensive Care Med 23:1212-8. 1997
    ..Our aim was to produce guidelines for the clinical application of inhaled NO in adult intensive care practice, based upon the current level of published information...
  98. ncbi The ventilatory stimulant doxapram inhibits TASK tandem pore (K2P) potassium channel function but does not affect minimum alveolar anesthetic concentration
    Joseph F Cotten
    Department of Anesthesia and Perioperative Care, University of California San Francisco, USA
    Anesth Analg 102:779-85. 2006
    ..Our data indicate that TASK-1 and TASK-3 do not play a role in mediating the immobility produced by halothane, although they are plausible molecular targets for the ventilatory effects of doxapram...
  99. ncbi Effect of some cardiac and respiratory drugs on succinate-cytochrome c reductase
    Mahmoud Balbaa
    Department of Chemistry, College of Science, Qatar University, P O Box 2713, Doha, Qatar
    J Enzyme Inhib Med Chem 19:343-7. 2004
    ..5 x 10(-5) and 5.7 x 10(-5)M, respectively. Moreover, neostigmine competitively inhibited the enzyme towards both substrates with Ki values of 1.36 x 10(-5) and 1.50 x 10(-5)M, respectively...
  100. ncbi European Respiratory Society--14th Annual Congress. Drug highlights. 4-8 September 2004, Glasgow, UK
    Saloni Shah
    Thomson Scientific, Middlesex House, 34-42 Cleveland Street, London, W1T 4JE, UK
    IDrugs 7:914-6. 2004
  101. ncbi LC/MS for the degradation profiling of cough-cold products under forced conditions
    A Marin
    Facultad de CC Experimentales y de la Salud, Universidad San Pablo CEU, Urbanizacion Monteprincipe, Boadilla del Monte, 28668 Madrid, Spain
    J Pharm Biomed Anal 35:1035-45. 2004
    ....

Research Grants41

  1. Role of Mucin in Lung Homeostasis and Pathophysiology
    Christopher M Evans; Fiscal Year: 2010
    ..Achievement of these goals will provide insights into novel treatments of obstructive lung diseases. ..
  2. Central Mechanisms of Respiratory Arrest
    Fadi Xu; Fiscal Year: 2007
    ....
  3. Prospective Study of Dietary Factors, BMI, and Risk of Asthma in Children
    Carlos Camargo; Fiscal Year: 2007
    ..The proposed study is cost-effective, as it makes use of an existing cohort, and it will provide information that could have direct clinical application to reduce risk of asthma. ..
  4. BACKGROUND POTASSIUM CHANNELS AS ANESTHETIC TARGETS
    CHARLES YOST; Fiscal Year: 2007
    ..An understanding of the basic mechanisms underlying anesthesia has the potential to lead to improved anesthetic drugs or techniques. ..
  5. Smoke Induced Airway Injury in COPD
    JEANINE D ARMIENTO; Fiscal Year: 2007
    ..The identification of transcription factors regulating protease expression in post smoke exposure will provide novel insight into the pathogenesis of COPD. ..
  6. Smoke Induced Airway Injury in COPD
    JEANINE M D apos ARMIENTO; Fiscal Year: 2010
    ..The identification of transcription factors regulating protease expression in post smoke exposure will provide novel insight into the pathogenesis of COPD. ..
  7. Smoke Induced Airway Injury in COPD
    JEANINE D ARMIENTO; Fiscal Year: 2009
    ..The identification of transcription factors regulating protease expression in post smoke exposure will provide novel insight into the pathogenesis of COPD. ..
  8. BACKGROUND POTASSIUM CHANNELS AS ANESTHETIC TARGETS
    CHARLES YOST; Fiscal Year: 2003
    ..With these experiments we expect that a more complete understanding of background K+ channels will emerge and their role in mediating the anesthetic state clarified. ..
  9. BACKGROUND POTASSIUM CHANNELS AS ANESTHETIC TARGETS
    CHARLES YOST; Fiscal Year: 2000
    ....
  10. CEREBELLUM--ROLE IN THE CHEMICAL CONTROL OF BREATHING
    Fadi Xu; Fiscal Year: 2003
    ..Perhaps, more exciting is the emerging concept that the cerebellum may be far more involved in the planning and executing of motor responses, including respiration, than we have heretofore imagined. ..
  11. Pathophysiology of Mucus Hypersecretion in Asthma
    Christopher Evans; Fiscal Year: 2003
    ..The project proposed here utilizes expertise and reagents available in his laboratory applies them to an important problem in asthma. ..
  12. DIET AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE
    Carlos Camargo; Fiscal Year: 2002
    ..The proposed study is cost-effective, as it makes use of an existing cohort, and it will provide information that could have direct clinical application to reduce risk of COPD. ..
  13. ALTERED MATRIX METALLOPROTEINASES IN HEART FAILURE
    JEANINE D ARMIENTO; Fiscal Year: 2002
    ..Finally, this proposal will investigate the role of interstitial collagenase (MMP-13) in cardiac function and development through the generation of an MMP-13 knockout mouse. ..
  14. POTASSIUM CHANNEL ACTIVATION BY VOLATILE ANESTHETICS
    CHARLES YOST; Fiscal Year: 2002
    ..Studies will be carried out in cerebellar granule neurons using whole cell ruptured patch and excised patch techniques on neurons in culture and in thin slices. ..